Stockscreener 앱 받기
4.98
0.20%
-0.010
시간 외 거래:
4.98
전일 마감가:
$4.99
열려 있는:
$5
하루 거래량:
11,941
Relative Volume:
0.06
시가총액:
$11.45M
수익:
-
순이익/손실:
$-58.52M
주가수익비율:
-2.3828
EPS:
-2.09
순현금흐름:
$-45.03M
1주 성능:
+1.63%
1개월 성능:
+959.57%
6개월 성능:
+516.57%
1년 성능:
+194.67%
1일 변동 폭
$4.91
$5.2112
1주일 범위
$4.76
$5.37
52주 변동 폭
$0.224
$5.37
Nextcure Inc Stock (NXTC) Company Profile
명칭
Nextcure Inc
전화
240-399-4900
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
NXTC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
4.98 | 11.45M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-03-05 | 업그레이드 | Truist | Hold → Buy |
| 2021-01-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-07-16 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-07-13 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-13 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-06-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-03-24 | 개시 | The Benchmark Company | Buy |
| 2020-03-02 | 개시 | ROTH Capital | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-05 | 개시 | Needham | Buy |
| 2019-11-26 | 개시 | BTIG Research | Buy |
| 2019-07-09 | 개시 | BofA/Merrill | Buy |
| 2019-06-03 | 개시 | Morgan Stanley | Overweight |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Nextcure Inc 주식(NXTC)의 최신 뉴스
Is NextCure Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
NextCure Inc. Stock Analysis and ForecastTriple-digit profit margins - jammulinksnews.com
What drives NextCure Inc. stock priceLightning-fast capital gains - jammulinksnews.com
What analysts say about NextCure Inc. stockRapid profit acceleration - jammulinksnews.com
What makes NextCure Inc. stock price move sharplyConsistent Growth Alert - Newser
Why NextCure Inc. stock attracts strong analyst attentionFree Access to Community - Newser
How NextCure Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Piper Sandler lowers NextCure stock price target to $15 after reverse split - Investing.com India
NextCure initiates one-for-twelve reverse stock split on Nasdaq By Investing.com - Investing.com Nigeria
NextCure Implements Reverse Stock Split on Nasdaq - TipRanks
NextCure initiates one-for-twelve reverse stock split on Nasdaq - Investing.com
NextCure Announces One-for-Twelve Reverse Stock Split - TipRanks
NextCure announces 1-for-12 reverse stock split effective July 14 - Investing.com Nigeria
NextCure announces 1-for-12 reverse stock split effective July 14 By Investing.com - Investing.com South Africa
NextCure’s (NXTC) Buy Rating Reaffirmed at HC Wainwright - Defense World
Eyes on Asia: AstraZeneca, NextCure, Sagimet Biosciences - BioXconomy
Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com
Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX
Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX
NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter
NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Home
NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable
NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener
Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com
NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks
NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus
NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia
Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com
Simcere Enters Strategic License Agreement with NextCure for Oncology Advancements - TipRanks
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire
NextCure Lands Massive $745M Deal for Revolutionary Cancer Drug: Phase 1 Trials Starting Q3 2025 - Stock Titan
Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail
Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025 - The Globe and Mail
Is Lucid Stock a Millionaire-Maker? - The Globe and Mail
JD.com Underperforms Industry in 3 Months: Should You Book Profits? - The Globe and Mail
Whitbread (LON:WTB) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Can Shopify's Expanding Merchant Base Sustain Its Growth Momentum? - The Globe and Mail
Baidu Bets Big on AI: Is the Cloud Business Finally Paying Off? - The Globe and Mail
SFIX Q3 Loss Narrower Than Expected, FY25 Outlook Raised, Stock Up 8% - The Globe and Mail
Nextcure Inc (NXTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):